Broadfin Capital Llc Trimmed Position in Mirati Therapeutics Inc (NASDAQ:MRTX) by $30.11 Million as Price Rose

May 17, 2018 - By James Douglas

Mirati Therapeutics, Inc. (NASDAQ:MRTX) Corporate LogoBig Money Sentiment increased to 2.21 in 2017 Q4. It has change of 1.04, from 2017Q3’s 1.17. The ratio improved due to MRTX positioning: 10 sold and 9 reduced. 27 funds acquired positions and 15 increased positions. Investors holded 13.25 million in 2017Q3 but now own 17.76 million shares or 34.00% more. Morgan Stanley accumulated 15,857 shs. Wells Fargo And Mn stated it has 0% of its capital in Mirati Therapeutics, Inc. (NASDAQ:MRTX). Baker Bros Advsrs L P, a New York-based fund reported 2.55 million shs. Alphamark Ltd Liability Corporation stated it has 0.01% of its capital in Mirati Therapeutics, Inc. (NASDAQ:MRTX). Jacobs Levy Equity has invested 0.01% in Mirati Therapeutics, Inc. (NASDAQ:MRTX). Raymond James Fincl Services Advisors has 0% invested in Mirati Therapeutics, Inc. (NASDAQ:MRTX) for 11,326 shs. Bogle Inv Mngmt Limited Partnership De owns 137,671 shs. Pnc Svcs Gru has invested 0% in Mirati Therapeutics, Inc. (NASDAQ:MRTX). Fin Architects holds 0% or 1,050 shs in its capital. Thompson Davis And holds 1,500 shs or 0.06% of its capital. Rock Springs Mgmt L P reported 0.15% stake. Dimensional Fund Advsrs Limited Partnership has 0% invested in Mirati Therapeutics, Inc. (NASDAQ:MRTX) for 334,567 shs. Moreover, Vanguard Gru Inc has 0% invested in Mirati Therapeutics, Inc. (NASDAQ:MRTX) for 1.02M shs. 34,818 are held by Eam Investors Ltd Liability Corp. Citigroup Incorporated owns 0% invested in Mirati Therapeutics, Inc. (NASDAQ:MRTX) for 41,524 shs.

MRTX had 7 insider sales and 0 insider buys since January 11, 2018. This’s net activity of $4.97 million. $1.41M worth of Mirati Therapeutics, Inc. (NASDAQ:MRTX) was sold by Donadio Jamie A on Thursday, March 1. BAUM CHARLES M sold 51,810 shs worth $1.45M.

The holdings In Mirati Therapeutics Inc (NASDAQ:MRTX) held by Kevin Kotler was reduced. According to 2018Q1 SEC form the reduction is 41.01%. By selling 1.00 million shares Broadfin Capital Llc made the stock Popped Up with 63.01%. At the end of 2018Q1, the 1.44M shares of the health care company held by the hedge fund run by Kevin Kotler were valued at $44.33M, down from 2.45M at the end of the previous reported quarter. Broadfin Capital Llc has risen its stake in Horizon Pharma Plc (NASDAQ:HZNP) and also increased its holding in Retrophin Inc (NASDAQ:RTRX) by 1.13M shares in the quarter, for a total of 1.18M shares.

Broadfin Capital is located in New York City and was founded by Kevin Kotler. Prior to Broadfin, Kotler could be found working for firms such as ING Barings, the Galleon Group, and ABN AMRO. Broadfin Capital Llc is a New York-based hedge fund that was founded by Kevin Kotler. It had more than $1.26 billion assets under management in December, 2014. Taken from Broadfin Capital latest Adv, the fund reported to have 10 full and part-time employees. Among which 5 performing investment advisory and research functions. The hedge fund had between 1-10 clients.

Mirati Therapeutics, Inc. (NASDAQ:MRTX) Ratings Coverage

In total 5 analysts cover Mirati Therapeutics (NASDAQ:MRTX). “Buy” rating has 5, “Sell” are 0, while 0 are “Hold”. (NASDAQ:MRTX) has 100% bullish analysts. 5 are the (NASDAQ:MRTX)’s ratings reports on May 17, 2018 according to StockzIntelligence Inc. On Thursday, December 21 the firm earned “Buy” rating by Cowen & Co. On Thursday, March 8 the firm has “Buy” rating given by SunTrust. On Wednesday, April 25 the stock has “Buy” rating by H.C. Wainwright. On Monday, March 5 Citigroup maintained the shares of MRTX in report with “Buy” rating.

Mirati Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of oncology products.The company has $1.03 billion market cap. The company's clinical stage product candidates include glesatinib, an orally-bioavailable, potent, small molecule kinase inhibitor that is in Phase II clinical trials for the treatment of non-small cell lung cancer patients with genetic alterations of MET; and in Phase Ib clinical trials in patients with genetic alterations of MET and Axl in NSCLC and other solid tumors.Last it reported negative earnings. The Company’s clinical stage product candidates also comprise sitravatinib, an orally-bioavailable, potent, small molecule spectrum-selective kinase inhibitor, which is in Phase II clinical trials for the treatment of solid tumors, such as NSCLC and metastatic Renal Cell Carcinoma, as well as in Phase Ib clinical trials to treat NSCLC patients with RET, CHR4q12, CBL, and AXL genetic alterations; and mocetinostat, an orally administered spectrum-selective Class 1 histone deacetylase inhibitor, which is in Phase Ib/II clinical trials in combination with durvalumab for the treatment of patients with NSCLC.

Mirati Therapeutics, Inc. (NASDAQ:MRTX) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: